Axsome Therapeutics Licenses Pfizer’s Potential Fibromyalgia Treatment Esreboxetine in US
News
Following an agreement with Pfizer, Axsome Therapeutics now has exclusive rights to develop and commercialize AXS-14 (esreboxetine) — a drug candidate for treatment of fibromyalgia — in the United States. ... Read more